Article Text

Download PDFPDF

P168/276  Intravenous dose-adjusted cangrelor use for neuroendovascular procedures: an institutional experience
  1. Harsh Desai1,
  2. Mohammed Maan Al-Salihi2,
  3. Rami Z Morsi1,
  4. Omar Vayani1,
  5. Sachin Kothari1,
  6. Sonam Thind1,
  7. Julian Carrion Penagos1,
  8. Ammar Tarabichi1,
  9. Archit Baskaran1,
  10. Veronica Bonderski1,
  11. Mary Hahn1,
  12. Scott Mendelson1,
  13. James R Brorson1,
  14. Elisheva Coleman1,
  15. Ali Mansour1,
  16. James Siegler3,
  17. Shyam Prabhakaran1,
  18. Italo Linfante4,
  19. Tareq Kass-Hout1
  1. 1University of Chicago Medical Center, Chicago, USA
  2. 2University of Wisconsin, Madison, USA
  3. 3Cooper Neurological Institute, Camden, USA
  4. 4Baptist Cardiac and Vascular Institute, Miami, USA


Introduction The safety and feasibility of intravenous cangrelor use for neuroendovascular procedures needs to be investigated.

Aim of Study To investigate safety and feasibility of intravenous dose-adjusted cangrelor in patients undergoing neuroendovascular procedures

Methods We conducted a retrospective study on patients who underwent neuroendovascular procedures and were placed on intravenous cangrelor. Cangrelor was administered as a 15 mcg/kg bolus followed by 2 mcg/kg/min infusion titrated to goal P2Y12 reaction unit (PRU) level of 50 to 150, then transitioned to oral antiplatelet therapy.

Results A total of 67 patients were included (mean age (years): 57.8 ± 18.5, males: 34 (50.7%), Black: 51 (76.1%)). The most common comorbidity was hypertension (n=38/66, 56.7%). Six patients (9.0%) received intravenous thrombolysis. Cangrelor infusion was used for stent placement (n=21, 32.3%). Stenting occurred intracranially in 18 patients, extracranially in 22 patients, and both intracranial and carotid arteries in 3 patients. PRU levels were measured in 61 patients (91.0%). Approximately 40.9% of the patients had favorable outcomes with modified Rankin Scale (mRS) score of 0 to 2 at 90 days (n=18/44). Within 1-year, 4 patients had recurrent/new strokes (7.7%), 2 with symptomatic intracranial hemorrhage [sICH] (3.0%), 3 with asymptomatic intracranial hemorrhage [aICH] (4.5%), and 1 gastrointestinal bleeding event were recorded (1.5%). When stratified by supratherapeutic PRU level (PRU < 50), there was a difference in sICH (p=0.044) but not aICH (p=0.203).

Conclusion This is the first report to demonstrate the safety and effectiveness of intravenous cangrelor use titrated by platelet function testing in neuroendovascular procedures.

Disclosure of Interest The authors have nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.